Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia 23Leukemia, Myeloid, Acute 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Multiple Myeloma 17Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Follicular 16Myelodysplastic Syndromes 15Lymphoma, Mantle-Cell 15Lymphoma 15Leukemia, Myeloid, Accelerated Phase 14Hodgkin Disease 14Blast Crisis 13Leukemia, Myelomonocytic, Chronic 12Lymphoma, Large-Cell, Immunoblastic 11Leukemia, Myeloid, Chronic-Phase 11Burkitt Lymphoma 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, B-Cell, Marginal Zone 10Congenital Abnormalities 10Neoplasms, Plasma Cell 9Breast Neoplasms 9Waldenstrom Macroglobulinemia 7Polycythemia Vera 7Leukemia, Biphenotypic, Acute 7Thrombocythemia, Essential 6Primary Myelofibrosis 6Carcinoma, Ovarian Epithelial 6

Interventions

Trastuzumab 3Paclitaxel 3Docetaxel 3Taxes 2Cyclophosphamide 2trastuzumab biosimilar HLX02 1tipifarnib 1romidepsin 1pertuzumab 1pegfilgrastim 1onvansertib 1neratinib 1grapiprant 1eribulin 1caficrestat 1Peripheral Blood Stem Cell Transplantation 1PF-05280014 1Ontruzant 1Ogivri 1Mesna 1Lapatinib 1Filgrastim 1Epirubicin 1Doxorubicin 1Depsipeptides 1Carboplatin 1Capecitabine 1Albumin-Bound Paclitaxel 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inflammatory Breast Neoplasms × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00002627 2014-01-10

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
30 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡